| P2093 | author name string | Malhotra A | |
| | Krilov LR | |
| P2860 | cites work | Influenza infection in humans and pigs in southeastern China | Q30423902 |
| | Emerging infections: pandemic influenza | Q30425597 |
| | Surveillance for pandemic influenza | Q30427935 |
| | Prospects for pandemic influenza control with currently available vaccines and antivirals | Q30427945 |
| | Improvement of inactivated influenza virus vaccines | Q30427949 |
| | Antivirals for pandemic influenza | Q30427953 |
| | Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment, and prevention | Q33339086 |
| | Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice | Q34199969 |
| | Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 |
| | Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group | Q34358628 |
| | The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children | Q34467468 |
| | Respiratory problems 2 years after acute bronchiolitis in infancy | Q35117216 |
| | Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada | Q35792916 |
| | Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. | Q36626174 |
| | Detection, pathogenesis, and therapy of respiratory syncytial virus infections | Q36632499 |
| | Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells | Q36687435 |
| | Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins. | Q36782773 |
| | Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines. | Q52531351 |
| | Molecular basis of resistance of influenza A viruses to amantadine. | Q54421224 |
| | Nebulized albuterol in acute bronchiolitis | Q68559848 |
| | Secretory antibody following oral influenza immunization | Q68926574 |
| | Respiratory syncytial viral infection in children with compromised immune function | Q69554112 |
| | Safe administration of influenza vaccine in asthmatic children hypersensitive to egg proteins | Q70114006 |
| | Influenza vaccine in unprimed children: improved immunogenicity with few reactions following one high dose of split-product vaccine | Q71215420 |
| | Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes | Q71932234 |
| | Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs | Q73551851 |
| | Preclinical development of low toxicity drugs: focus on zanamivir, an anti-influenza drug | Q36898600 |
| | Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity | Q36919232 |
| | Intracellular neutralization of virus by immunoglobulin A antibodies | Q37126877 |
| | Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus | Q37207762 |
| | From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses | Q37874142 |
| | Influenza: status and prospects for its prevention, therapy, and control | Q37928996 |
| | T-cell recognition of influenza viral antigens | Q38177210 |
| | Respiratory syncytial virus infections in infants and children: diagnosis and treatment | Q39703137 |
| | Determinants of immunity to influenza infection in man | Q39784922 |
| | Prospects for a respiratory syncytial virus vaccine | Q40625380 |
| | Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody. | Q40695684 |
| | Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant | Q40724719 |
| | Toxic shock syndrome complicating influenza A in a child: case report and review | Q40835648 |
| | Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children | Q41077230 |
| | Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. | Q41098585 |
| | Variation in severity of respiratory syncytial virus infections with subtype | Q41194455 |
| | A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees | Q41458369 |
| | Development of novel influenza virus vaccines and vectors | Q41548240 |
| | CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells | Q41622552 |
| | Influenza vaccines. A reappraisal of their use. | Q41676828 |
| | Respiratory syncytial virus-immunoglobulin intravenous (RSV-IGIV) for respiratory syncytial viral infections: part I. | Q41678107 |
| | Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection | Q41729050 |
| | Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life | Q42628288 |
| | Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines | Q43746561 |
| | Neonatal respiratory syncytial virus infection | Q44267961 |
| | Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study | Q44603480 |
| | Association of serum anti-neuraminidase antibody with resistance to influenza in man. | Q44693807 |
| | Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans | Q44817736 |
| | Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium | Q44847089 |
| | Modes of transmission of respiratory syncytial virus | Q44967172 |
| | Nosocomial Respiratory Syncytial Virus Infections | Q45076178 |
| | A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection | Q45148150 |
| | Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group | Q45753199 |
| | Influenza virus infections in infants | Q45759256 |
| | DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs | Q45761440 |
| | Severity of respiratory syncytial virus infection is related to virus strain | Q45764062 |
| | Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group | Q45764623 |
| | Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis | Q45769900 |
| | Immune response of human volunteers and animals to vaccination with egg-grown influenza A (H1N1) virus is influenced by three amino acid substitutions in the haemagglutinin molecule | Q45773498 |
| | A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine | Q45773865 |
| | Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit | Q45780126 |
| | Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine | Q45781115 |
| | Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine | Q45781116 |
| | Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development | Q45785065 |
| | Albuterol responsiveness in infants with respiratory failure caused by respiratory syncytial virus infection | Q45787375 |
| | Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus | Q45788449 |
| | Respiratory syncytial virus infection causing neurological disorder in neonates | Q45806564 |
| | Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection | Q45830786 |
| | Efficacy of sequential annual vaccination with inactivated influenza virus vaccine | Q45832445 |
| | Immunization of cotton rats with the human respiratory syncytial virus F glycoprotein produced using a baculovirus vector | Q45844009 |
| | Influenza virus RNA in the lung and lymphoid tissue of immunologically intact and CD4-depleted mice | Q45860583 |
| | Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine | Q45868053 |
| | Does influenza vaccination exacerbate asthma? | Q50159833 |
| | The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. | Q50852734 |
| P433 | issue | 2 | |
| P304 | page(s) | 353-72, vi-vii | |
| P577 | publication date | 2000-04-01 | |
| P1433 | published in | Pediatric Clinics of North America | Q7159204 |
| P1476 | title | Influenza and respiratory syncytial virus. Update on infection, management, and prevention | |
| P478 | volume | 47 | |